PPD sells rights to inhibitors for $15M up front

PPD has gained a deal to sell its development and marketing rights to all dipeptidyl peptidase IV inhibitors to Takeda for $15 million up front along with unspecified milestones for any successful product development. PPD gained the rights in an earlier deal with Syrrx. Takeda bought Syrrx in March and renamed it Takeda San Diego.

- read this press release for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.